Mifeprex (mifepristone) / Danco Laboratories 
Welcome,         Profile    Billing    Logout  
 94 Diseases   58 Trials   58 Trials   2914 News 


«12...345678910111213...3839»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Mifeprex (mifepristone) / Danco Laboratories
    Phase II study of pembrolizumab plus mifepristone in patients with advanced HER2-negative breast cancer. (On Demand | Hall A; Poster Bd # 316) -  Apr 26, 2023 - Abstract #ASCO2023ASCO_3287;    
    P2
    In addition, a higher than anticipated rate of skin toxicity, possibly related to mifepristone enhancing the activity of ICI, was observed in the study, leading to early closure. While the benefit/risk analysis of this combination does not support further evaluation, additional investigation of alternative chemotherapy-free, immunomodulatory strategies is warranted.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Journal:  Court Intrusion Into Science and Medicine-the Mifepristone Decisions. (Pubmed Central) -  Apr 26, 2023   
    While the benefit/risk analysis of this combination does not support further evaluation, additional investigation of alternative chemotherapy-free, immunomodulatory strategies is warranted. No abstract available
  • ||||||||||  NN1213 / Novo Nordisk, Mifeprex (mifepristone) / Danco Laboratories
    Enrollment change, Trial termination:  Medication Enhanced Rapid Therapy (clinicaltrials.gov) -  Apr 26, 2023   
    P1,  N=15, Terminated, 
    No abstract available N=90 --> 15 | Suspended --> Terminated; COVID and staffing issues
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Journal:  Judicial interference with mifepristone. (Pubmed Central) -  Apr 24, 2023   
    Not yet recruiting --> Recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Apr 2023 --> Dec 2023 No abstract available
  • ||||||||||  lithium carbonate ER / Generic mfg.
    Journal:  An update on potential pharmacotherapies for cognitive impairment in bipolar disorder. (Pubmed Central) -  Apr 17, 2023   
    Traditional treatments, such as lithium, anticonvulsants (lamotrigine), antipsychotics (aripiprazole, asenapine, cariprazine, lurasidone, and olanzapine), antidepressants (vortioxetine, fluoxetine, and tianeptine) and psychostimulants (modafinil), and emerging interventions, such as acetylcholinesterase inhibitors (galantamine and donepezil), dopamine agonists (pramipexole), erythropoietin, glucocorticoid receptor antagonists (mifepristone), immune modulators (infliximab, minocycline and doxycycline), ketamine, metabolic agents (insulin, metformin, and liraglutide), probiotic supplements, and Withania somnifera are discussed...In the past, methodological pitfalls in BD cognition trials have also been a critical limiting factor. Expanding on the existing literature and identifying novel pharmacological and non-pharmacological treatments for cognitive impairment in BD should be a priority.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Trial completion date, Trial primary completion date:  Mail Order Mifepristone Study (clinicaltrials.gov) -  Apr 12, 2023   
    P4,  N=538, Active, not recruiting, 
    Therefore, our study identified the potential therapeutic use of relacorilant in combination with somatostatin analogs and demonstrated the advantages of relacorilant over Mifepristone, supporting its further development for use in the treatment of CD patients. Trial completion date: Jan 2023 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Jun 2023